Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 6—June 2012


Pretransplant Fecal Carriage of Extended-Spectrum β-Lactamase–producing Enterobacteriaceae and Infection after Liver Transplant, France

Frédéric BertComments to Author , Béatrice Larroque, Catherine Paugam-Burtz, Federica Dondero, François Durand, Estelle Marcon, Jacques Belghiti, Richard Moreau, and Marie-Hélène Nicolas-Chanoine
Author affiliations: Hôpital Beaujon, Clichy, France (F. Bert, B. Larroque, C. Paugam-Burtz, F. Dondero, F. Durand, E. Marcon, J. Belghiti, R. Moreau, M.H. Nicolas-Chanoine); Université Paris VII Faculté de Médecine D. Diderot, Paris, France (C. Paugam-Burtz, F. Durand, J. Belghiti, M.H. Nicolas-Chanoine); INSERM U 773 Centre de Recherche Biomédicale Bichat-Beaujon, CRB3, Paris (F. Durand, R. Moreau, M.H. Nicolas-Chanoine)

Main Article

Table 5

Risk factors for ESBLE infection after liver transplant, by stepwise logistic regression analysis, France, January 2001–April 2010*

Variable† OR (95% CI) p value
Pretransplant ESBLE fecal carriage 18.4 (7.1–47.5) <0.0001
MELD score >25 2.9 (1.4–6.2) 0.0053
Return to surgery 2.7 (1.3–5.9) 0.011

*ESBLE, extended-spectrum β-lactamase-producing Enterobacteriaceae; OR, odds ratio; MELD, Model for End-stage Liver Disease.
†Other factors initially in the model were hepatocellular carcinoma, acute liver failure, pretransplant ICU stay >48h, hospital stay >10 d in the 6 mo before transplant, spontaneous bacterial peritonitis in the 6 mo before transplant, red blood cells transfused, and posttransplant acute renal failure.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO